Standout Papers
Citation Impact
Citing Papers
Direct oral anticoagulants for treatment of HIT: update of Hamilton experience and literature review
2017
Fondaparinux for the treatment of suspected heparin-induced thrombocytopenia: a propensity score–matched study
2014
Clinical outcomes in a cohort of patients with heparin‐induced thrombocytopenia
2017
American Society of Hematology 2018 guidelines for management of venous thromboembolism: heparin-induced thrombocytopenia
2018 Standout
A review of 122 published outcomes of danaparoid anticoagulation for intermittent haemodialysis
2009
Pharmacokinetics and pharmacodynamics of danaparoid during continuous venovenous hemofiltration: a pilot study
2007
Nonheparin Anticoagulants for Heparin-Induced Thrombocytopenia
2013
Parenteral Anticoagulants
2012 Standout
CLINICAL PRACTICE. Heparin-Induced Thrombocytopenia.
2015
Application, tolerance and safety of fondaparinux therapy in a German hospital: A prospective single-centre experience
2011
Argatroban Anticoagulation for Heparin-Induced Thrombocytopenia in Elderly Patients
2007
Heparin-Induced Thrombocytopenia: A Serious Complication of Heparin Therapy for Acute Stroke
2008
Pediatric Heparin-Induced Thrombocytopenia: Prevalence, Thrombotic Risk, and Application of the 4Ts Scoring System
2014
Anti-platelet factor 4/polyanion antibodies mediate a new mechanism of autoimmunity
2017
Antithrombotic Therapy for VTE Disease
2016 Standout
Heparin‐induced thrombocytopenia: a prospective study on the incidence, platelet‐activating capacity and clinical significance of antiplatelet factor 4/heparin antibodies of the IgG, IgM, and IgA classes
2007
Thrombotic Thrombocytopenic Purpura and Heparin-Induced Thrombocytopenia: Two Unique Causes of Life-Threatening Thrombocytopenia
2009
Disease burden, complication rates, and health-care costs of heparin-induced thrombocytopenia in the USA: a population-based study
2018
Treatment and Prevention of Heparin-Induced Thrombocytopenia
2008 Standout
Clinical and laboratory diagnosis of heparin induced thrombocytopenia: an update
2017
Management of the multiple phases of heparin-induced thrombocytopenia
2016
Antithrombotic Therapy for VTE Disease
2012 Standout
Prevalence and Risk of Preexisting Heparin-Induced Thrombocytopenia Antibodies in Patients With Acute VTE
2011
A Novel PF4-Dependent Platelet Activation Assay Identifies Patients Likely to Have Heparin-Induced Thrombocytopenia/Thrombosis
2016
Prevalence and clinical implications of anti-PF4/heparin antibodies in intensive care patients: a prospective observational study
2014
Executive Summary
2012 Standout
Platelet response to direct thrombin inhibitor or fondaparinux treatment in patients with suspected heparin-induced thrombocytopenia
2018
Heparin-Induced Thrombocytopenia
2006 Standout
Quantitative interpretation of optical density measurements using PF4‐dependent enzyme‐immunoassays
2008
Negative Heparin-Induced Thrombocytopenia Test Result After Massive Transfusion
2016
Argatroban therapy in heparin-induced thrombocytopenia
2008
Testing for Heparin-Induced Thrombocytopenia Antibodies
2006
Bivalirudin for the treatment of patients with confirmed or suspected heparin‐induced thrombocytopenia
2014
Treatment and Prevention of Heparin-Induced Thrombocytopenia
2012
The European guideline on management of major bleeding and coagulopathy following trauma: fourth edition
2016 Standout
Think of HIT
2006
The HIT Expert Probability (HEP) Score: a novel pre‐test probability model for heparin‐induced thrombocytopenia based on broad expert opinion
2010
Heparin‐induced multi‐electrode aggregometry method for heparin‐induced thrombocytopenia testing: communication from the SSC of the ISTH
2016
Update on Systemic Prostate Cancer Therapies: Management of Metastatic Castration-resistant Prostate Cancer in the Era of Precision Oncology
2018
Heparin-Induced Thrombocytopenia
2016
Guidelines for the Prevention of Intravascular Catheter-related Infections
2011 Standout
Heparin-induced Thrombocytopenia, a Prothrombotic Disease
2007
Diagnosis, Treatment, and Long-Term Management of Kawasaki Disease: A Scientific Statement for Health Professionals From the American Heart Association
2017 Standout
Thrombocytopenia Associated with Antithrombotic Therapy in Patients with Cardiovascular Diseases
2008
Distinguishing between anti–platelet factor 4/heparin antibodies that can and cannot cause heparin‐induced thrombocytopenia
2015
Incidence and Prognostic Significance of Thrombocytopenia in Patients Treated With Prolonged Heparin Therapy
2008
Clinical picture of heparin-induced thrombocytopenia (HIT) and its differentiation from non-HIT thrombocytopenia
2016
Heparin-induced multiple electrode aggregometry is a promising and useful functional tool for heparin-induced thrombocytopenia diagnosis: Confirmation in a prospective study
2012
HITlights: A career perspective on heparin‐induced thrombocytopenia
2012
Guidelines on the Use of Therapeutic Apheresis in Clinical Practice – Evidence‐Based Approach from the Writing Committee of the American Society for Apheresis: The Eighth Special Issue
2019 Standout
Guidelines for the Early Management of Patients With Acute Ischemic Stroke
2013 Standout
Heparin Reexposure in Patients With a History of Heparin-Induced Thrombocytopenia
2015
Predictive value of the 4Ts scoring system for heparin-induced thrombocytopenia: a systematic review and meta-analysis
2012
Platelet transfusions in heparin‐induced thrombocytopenia: a report of four cases and review of the literature
2008
Heparin-Induced Thrombocytopenia Screening and Management in Pediatric Patients
2011
High sensitivity and specificity of a new functional flow cytometry assay for clinically significant heparin‐induced thrombocytopenia antibodies
2013
Management of anticoagulation in patients with subacute heparin-induced thrombocytopenia scheduled for heart transplantation
2008
Management of Massive and Submassive Pulmonary Embolism, Iliofemoral Deep Vein Thrombosis, and Chronic Thromboembolic Pulmonary Hypertension
2011 Standout
Prevention and Treatment of Thrombosis in Pediatric and Congenital Heart Disease
2013
The severity of trauma determines the immune response to PF4/heparin and the frequency of heparin-induced thrombocytopenia
2009
Lutetium-177–PSMA-617 for Metastatic Castration-Resistant Prostate Cancer
2021 Standout
Plasma exchange to remove HIT antibodies: dissociation between enzyme-immunoassay and platelet activation test reactivities
2014
Guidelines on the diagnosis and management of heparin‐induced thrombocytopenia: second edition
2012
2015 ESC Guidelines for the management of acute coronary syndromes in patients presenting without persistent ST-segment elevation
2015 Standout
Thrombotic Thrombocytopenia after ChAdOx1 nCov-19 Vaccination
2021 Standout
A prospective, blinded study of a PF4-dependent assay for HIT diagnosis
2020
Fondaparinux and the Management of Heparin-Induced Thrombocytopenia: The Journey Continues
2009
Survival with Olaparib in Metastatic Castration-Resistant Prostate Cancer
2020
Pathologic Antibodies to Platelet Factor 4 after ChAdOx1 nCoV-19 Vaccination
2021 Standout
2014 AHA/ACC Guideline for the Management of Patients With Non–ST-Elevation Acute Coronary Syndromes
2014 Standout
Hematological Problems in Pediatric Intensive Care
2013 Standout
Thrombosis and Thrombocytopenia after ChAdOx1 nCoV-19 Vaccination
2021 Standout
Works of Gregory Lo being referenced
What is the potential for overdiagnosis of heparin‐induced thrombocytopenia?
2007
Evaluation of pretest clinical score (4 T's) for the diagnosis of heparin‐induced thrombocytopenia in two clinical settings
2006 Standout
Treatment Outcomes and Tumor Loss of Heterozygosity in Germline DNA Repair–deficient Prostate Cancer
2017
Towards a Conceptual Framework for Diagnosis of Heparin-Induced Thrombocytopenia (HIT).
2005